Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

被引：0
作者：
J Bray
J Sludden
M J Griffin
M Cole
M Verrill
D Jamieson
A V Boddy
机构：
[1] Northern Institute for Cancer Research,
[2] Paul O'Gorman Building,undefined
[3] Medical School,undefined
[4] Newcastle University,undefined
[5] Northern Centre for Cancer Care,undefined
[6] Newcastle Freeman Hospital,undefined
来源：
British Journal of Cancer | 2010年 / 102卷
关键词：
breast cancer; doxorubicin; cyclophosphamide; pharmacogenetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1003 / 1009
页数：6
相关论文
共 50 条
  • [41] Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer
    Hardenbergh, PH
    Recht, A
    Gollamudi, S
    Come, SE
    Hayes, DF
    Shulman, LN
    O'Neill, A
    Gelman, RS
    Silver, B
    Harris, JR
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (01): : 69 - 72
  • [42] Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin
    Angel Qin
    Cheryl L. Thompson
    Paula Silverman
    Journal of Cancer Survivorship, 2015, 9 : 252 - 259
  • [43] Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin
    Qin, Angel
    Thompson, Cheryl L.
    Silverman, Paula
    JOURNAL OF CANCER SURVIVORSHIP, 2015, 9 (02) : 252 - 259
  • [44] INTERACTION OF PUFAS AND DOXORUBICIN: THE ENHANCED TOXICITY IN BREAST CANCER CELLS
    Zajdel, Alicja
    Wilczok, Adam
    ACTA POLONIAE PHARMACEUTICA, 2023, 80 (05): : 747 - 754
  • [45] Cardiovascular toxicity of the first line cancer chemotherapeutic agents:: doxorubicin, cyclophosphamide, streptozotocin and bevacizumab
    Drimal, Jan
    Zurova-Nedelcevova, Jana
    Knezl, Vladimir
    Sotnikova, Ruzena
    Navarova, Jana
    NEUROENDOCRINOLOGY LETTERS, 2006, 27 : 176 - 179
  • [46] Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide
    Dempsey, CL
    Coop, AJ
    Shillington, A
    Farley, PA
    Eberhardt, DR
    O'Briant, S
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (08) : 781 - 786
  • [47] Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer
    Dumet Fernandes, Bruno Jose
    Silva, Carolina de Miranda
    Andrade, Jurandyr Moreira
    Silva Matthes, Angelo do Carmo
    Coelho, Eduardo Barbosa
    Lanchote, Vera Lucia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (04) : 897 - 904
  • [48] Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer
    Bruno José Dumêt Fernandes
    Carolina de Miranda Silva
    Jurandyr Moreira Andrade
    Ângelo do Carmo Silva Matthes
    Eduardo Barbosa Coelho
    Vera Lucia Lanchote
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 897 - 904
  • [49] Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines
    Ando, M
    Narabayashi, M
    Watanabe, T
    Kamiya, Y
    Togitani, K
    Tanosaki, R
    Takenaka, T
    Tobinai, K
    Adachi, I
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1999, 29 (01) : 28 - 32
  • [50] Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study
    Linot, B.
    Campone, M.
    Augereau, P.
    Delva, R.
    Abadie-Lacourtoisie, S.
    Nebout-Mesgouez, N.
    Capitain, O.
    JOURNAL OF NEURO-ONCOLOGY, 2014, 117 (02) : 253 - 259
12345